March 16, 2020 / 5:21 PM / 22 days ago

BRIEF-Moderna Announces First Participant Dosed In Nih-Led Phase 1 Study Of Mrna Vaccine Against Novel Coronavirus

March 16 (Reuters) - Moderna Inc:

* MODERNA ANNOUNCES FIRST PARTICIPANT DOSED IN NIH-LED PHASE 1 STUDY OF MRNA VACCINE (MRNA-1273) AGAINST NOVEL CORONAVIRUS

* MODERNA - PREPARING FOR POTENTIAL PHASE 2 STUDY UNDER ITS OWN IND TO BUILD ON DATA FROM ONGOING PHASE 1 STUDY OF VACCINE AGAINST NOVEL CORONAVIRUS

* MODERNA INC - MANUFACTURE OF MRNA-1273 MATERIAL FOR POTENTIAL PHASE 2 TRIAL, WHICH COULD BEGIN IN A FEW MONTHS, IS UNDERWAY Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below